Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study.
de Simone G, Chinali M, Mureddu GF, Cacciatore G, Lucci D, Latini R, Masson S, Vanasia M, Maggioni AP, Boccanelli A; AREA-in-CHF Investigators. de Simone G, et al. Among authors: vanasia m. Nutr Metab Cardiovasc Dis. 2011 Oct;21(10):783-91. doi: 10.1016/j.numecd.2010.02.012. Epub 2010 Jun 17. Nutr Metab Cardiovasc Dis. 2011. PMID: 21939839 Clinical Trial.
Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results.
Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni AP, Masson S, Vanasia M, de Simone G; AREA IN-CHF Investigators. Boccanelli A, et al. Among authors: vanasia m. Eur J Heart Fail. 2009 Jan;11(1):68-76. doi: 10.1093/eurjhf/hfn015. Eur J Heart Fail. 2009. PMID: 19147459 Free article. Clinical Trial.
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study.
Derosa G, Maffioli P, Scelsi L, Bestetti A, Vanasia M, Cicero AFG, Spinardi L, Bentivenga C, Esposti DD, Caprio M, Borghi C, Pitt B, Cosentino E. Derosa G, et al. Among authors: vanasia m. Pharmacol Res. 2019 Mar;141:46-52. doi: 10.1016/j.phrs.2018.11.037. Epub 2018 Nov 28. Pharmacol Res. 2019. PMID: 30502530
Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
Boccanelli A, Cacciatore G, Mureddu GF, de Simone G, Clemenza F, De Maria R, Di Lenarda A, Gavazzi A, Latini R, Masson S, Porcu M, Vanasia M, Gonzini L, Maggioni AP. Boccanelli A, et al. Among authors: vanasia m. J Cardiovasc Med (Hagerstown). 2007 Sep;8(9):683-91. doi: 10.2459/JCM.0b013e3281053a9a. J Cardiovasc Med (Hagerstown). 2007. PMID: 17700397 Free article. Clinical Trial.
Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure.
Clemenza F, Masson S, Conaldi PG, Di Carlo D, Boccanelli A, Mureddu GF, Gonzini L, Lucci D, Maggioni AP, Di Lenarda A, Nicolis EB, Vanasia M, Latini R; AREA IN-CHF Investigators. Clemenza F, et al. Among authors: vanasia m. Circ J. 2017 Sep 25;81(10):1543-1546. doi: 10.1253/circj.CJ-17-0656. Epub 2017 Aug 31. Circ J. 2017. PMID: 28855452 Free article. Clinical Trial.
Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
Derosa G, Maffioli P, D'Avino M, Sala C, Mugellini A, Vulpis V, Felis S, Guasti L, Sarzani R, Bestetti A, Vanasia M, Gaudio G; ESCAPE-IT Trial Investigators group. Derosa G, et al. Among authors: vanasia m. Cardiovasc Ther. 2017 Feb;35(1):47-54. doi: 10.1111/1755-5922.12235. Cardiovasc Ther. 2017. PMID: 27860389 Free PMC article. Clinical Trial.
Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients.
Guasti L, Gaudio G, Lupi A, D'Avino M, Sala C, Mugellini A, Vulpis V, Felis S, Sarzani R, Vanasia M, Maffioli P, Derosa G. Guasti L, et al. Among authors: vanasia m. Drug Des Devel Ther. 2017 Aug 4;11:2293-2300. doi: 10.2147/DDDT.S134826. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28831241 Free PMC article. Clinical Trial.
15 results